Personalized care. One $109/month membership. Explore membership
Weight Management
Zepbound Injectable medication pen
LEXA HEALTH / WEIGHT MANAGEMENT

Zepbound injection

Tirzepatide

Tirzepatide acts on both GIP and GLP-1 receptors to support weight management.

Administration
Weekly injection
Clinical evaluation
Required before prescribing
Membership
$109/month · Medication billed separately
Get Started

Availability and suitability depend on individual evaluation. Membership does not guarantee a prescription.

Understanding Zepbound injection

Zepbound is an FDA-approved prescription medicine used with a reduced-calorie diet and increased physical activity for long-term weight management in eligible adults. It is not a substitute for an individualized care plan.

How it works

Tirzepatide activates two hormone receptors: GIP and GLP-1. These pathways help regulate appetite and food intake. It also slows stomach emptying, especially early in treatment, and affects insulin release when blood sugar is elevated.

How it is administered

Inject under the skin once a week, on the same day, with or without meals. The abdomen, thigh or upper arm may be used according to the instructions for your prescribed device. Your clinician starts at a lower dose and increases gradually; 15 mg is a study dose, not a starting dose.

Clinical research & results

In SURMOUNT-1 (label Study 1), the 15 mg group averaged 20.9% weight reduction at 72 weeks, compared with 3.1% with placebo. This analysis includes participants regardless of treatment discontinuation. The study excluded diabetes; results in people with type 2 diabetes differed.

These are separate trials, not a direct comparison between medicines. Study averages do not establish which medicine is best for you.

Zepbound full prescribing information
THE RESEARCH, IN CONTEXT

What could the study average look like?

An educational illustration of 20.9% weight reduction over 72 weeks.

SURMOUNT-1 · Study 1 · 15 mg weekly

Adults with obesity (BMI ≥30), or overweight (BMI ≥27) with at least one weight-related condition, without diabetes. Participants also received reduced-calorie diet and physical-activity support.

lbs
100 lbs500 lbs
Illustrative pounds lost≈ 52 lbs
Illustrative remaining weight≈ 198 lbs

20.9% average reduction · 72 weeks

These figures represent average results observed in clinical trials and are provided for educational purposes only. Individual results vary. Actual outcomes depend on individual health factors, treatment response, adherence, and other considerations. Results are not guaranteed. Medication is prescribed only following an individualized clinical evaluation.

Common side effects

Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, injection-site reactions and fatigue. Side effects and tolerability should be reviewed during follow-ups.

Safety & important considerations

  • Do not use with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a serious allergy to the medication. These products carry a boxed thyroid C-cell tumor warning; the risk in humans is unknown.
  • Serious risks include pancreatitis, gallbladder problems, dehydration-related kidney injury and severe digestive symptoms. These medicines are not recommended in severe gastroparesis. Seek urgent care for persistent severe abdominal pain, serious allergic symptoms, or sudden vision changes.
  • Tell your clinician about all medicines, diabetes-related eye disease, planned anesthesia or deep sedation, and pregnancy plans. Low blood sugar risk can increase with insulin or sulfonylureas. Do not combine with other GLP-1 medicines; your clinician reviews interactions and suitability.
  • Stop Zepbound when pregnancy is recognized and contact your clinician. Oral contraceptive users should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase. The current label also warns about non-arteritic anterior ischemic optic neuropathy (NAION); sudden vision loss needs immediate assessment.

This is a summary, not a complete list of risks or instructions. Read the full prescribing information and Medication Guide and speak with your clinician.

Read official safety information
YOUR QUESTIONS

More about Zepbound injection

Does acting on two receptors guarantee more weight loss?

No. The mechanism does not predict an individual outcome. The calculator uses one Zepbound trial, not a head-to-head comparison or a recommendation over another medicine.

Will I start at 15 mg?

No. The label starts at a lower introductory dose, followed by clinician-directed increases. Not everyone needs or tolerates the highest dose.

Can I take it with Wegovy or Ozempic?

Combining Zepbound with other tirzepatide-containing products or any GLP-1 receptor agonist is not recommended.

Care begins with a conversation.

Explore a personalized plan with Lexa Health.

Get Started